Not all of these writers might be considered “Western,” yet each of them are featured on this quarter’s syllabus for Stanford’s Structured Liberal Education (SLE) program. This reflects a ...

SANTA MONICA, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Super League Enterprise, Inc. (NASDAQ: SLE) (the “Company”), a leader in redefining how brands connect with consumers through the power ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that causes widespread inflammation. It can affect the skin, joints, blood vessels, and multiple organ systems. The exact cause ...

Super League Enterprise (SLE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $3.47 per share a year ago.

Both flare and persistently active disease (PAD) are common disease activity patterns in patients with systemic lupus erythematosus (SLE). A large prospective multinational cohort study ...

Prolonged remission was observed in 72% of patients with systemic lupus erythematosus (SLE) who were treated with a consistent 200 mg daily dose of hydroxychloroquine. The mean weight-adjusted ...

WASHINGTON — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications appear beneficial for people with systemic lupus erythematosus (SLE) and lupus nephritis, two new studies suggest.

Systemic lupus erythematosus (SLE) is the most common form of lupus — it’s the type that 7 in 10 people with lupus have. It's what most people mean when they say "lupus." Experts don’t know what ...